Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies.
|
8049356 |
1994 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In RA, plasma S100A4 correlated with increased CSF2, and increased PRDM8 transcription in RA monocytes was associated with increased plasma CCL5 and IL-6, as well as therapy-resistance.
|
31037071 |
2019 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study therefore identifies convergent MAPK pathways on Ser345 that are involved in GM-CSF- and TNF-alpha-induced priming of neutrophils and are activated in RA.
|
16778989 |
2006 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.
|
2026869 |
1991 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The TTP pathway of TNF-alpha and GM-CSF mRNA degradation is a possible novel target for anti-TNF-alpha therapies for rheumatoid arthritis, and also for other conditions proven to respond to anti-TNF-alpha therapy.
|
15535838 |
2004 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF and granulocyte macrophage-colony stimulating factor (GM-CSF) have proinflammatory activity and both contribute, for example, to rheumatoid arthritis pathogenesis.
|
29563337 |
2018 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
DC-SIGN expression on RA monocytes or on monocytes stimulated with granulocyte-macrophage colony-stimulating factor and interleukin-4 was further investigated by flow cytometry.
|
12571844 |
2003 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in the presence of RANKL and macrophage colony-stimulating factor, differentiation and activation of human osteoclasts were also suppressed by DHMEQ, suggesting the possibility of future application of NF-kappaB inhibitors to rheumatoid arthritis therapy.
|
17892600 |
2007 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas, CM3D was characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10 and LIF, along with trophic factors involved in different mechanisms leading to tissue regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis (RA).
|
30804924 |
2019 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mRNAs encoding RANKL, RANK, OPG and macrophage-colony stimulating factor were expressed by cells isolated from RA joints.
|
11426018 |
2001 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 1-beta (IL-1 beta), IL-2, IL-4, IL-5, IL-6, IL-8, tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and granulocyte-macrophage colony-stimulating factor (GM-CSF) gene expression was determined in knee synovium of 16 patients with rheumatoid arthritis (RA) and 16 patients with seronegative spondyloarthropathies (SSP), by using polymerase chain reaction (PCR) amplification.
|
9117172 |
1997 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphisms in several genes were associated with IL-6 levels (including IL10, TYK2, and CD40L in SLE and DRB1, NOD2, and CSF1 in RA) or with TNFα levels (including TNFSF4 and CSF2 in SLE and PTPN2, DRB1, and NOD2 in RA).
|
25652333 |
2015 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, this combination suppressed more IFN-γ secretion and NFAT-regulated gene (GM-CSF and IFN-γ) expression in RA-MNCs than normal MNCs via decreasing the activity of NFATc1.
|
22385242 |
2012 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, GM-CSF in SFs existed at a significant level in the patients with RA (n = 6), in comparison with the other inflammatory cytokines, IL-1beta and TNF-alpha.
|
17101062 |
2006 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings demonstrate that IL-17 regulates SHP-2 expression and IL-17RA/STAT-3 dependent production of Cyr61, IL-23, GM-CSF and RANKL in AA-FLS and may reveal a new insight into the pathogenesis of RA.
|
28898718 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA.
|
28213566 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
|
30358109 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
|
22446963 |
2012 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis.
|
2504878 |
1989 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conversely, Th17 cells and their effector molecules interleukin 17A (IL-17A), IL-17F, interferon (IFN)γ, tumor necrosis factor (TNF)α, and granulocyte-macrophage colony-stimulating factor (GM-CSF) are implicated in the pathology of rheumatoid arthritis (RA).
|
29254845 |
2018 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF-mediated inflammation has also been implicated in certain types of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
|
25803788 |
2015 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
|
21613310 |
2011 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several in vitro and in vivo studies showed that granulocyte-macrophage colony-stimulating factor (GM-CSF), known to be a hematopoietic factor, is also one of the proinflammatory cytokines involved in macrophage activation, crucial for the pathogenic network of RA.
|
28144129 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
|
29069507 |
2018 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.
|
16859503 |
2006 |